Dealmaker Sabry retiring from Roche after 14-year stint

Prolific dealmaker James Sabry is stepping away from Roche (SIX:ROG: OTCQX:RHHBY) and its Genentech Inc. subsidiary after a 14-year run with the company, including the past six years as the pharma’s global head of partnering.

Roche described Sabry’s departure as his retirement from the company, although it’s not clear what next steps may lie ahead for the executive...